|
시장보고서
상품코드
2081969
광간섭 단층촬영(OCT) 시장 : 제품 유형, 구성 요소, 기술, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)Optical Coherence Tomography Market by Product Type, Component, Technology, Application, End User - Global Forecast 2026-2032 |
||||||
360iResearch
광간섭 단층촬영(OCT) 시장은 2032년까지 연평균 복합 성장률(CAGR) 9.08%로 성장해 40억 1,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도(2025년) | 21억 8,000만 달러 |
| 추정 연도(2026년) | 23억 6,000만 달러 |
| 예측 연도(2032년) | 40억 1,000만 달러 |
| CAGR(%) | 9.08% |
광간섭 단층촬영(OCT)은 조직의 미세 구조를 고해상도로 단면 영상화하는 핵심 영상 진단법으로, 안과 분야에서 임상 도입이 가장 활발하며, 순환기내과, 피부과, 종양학과, 내시경 검사 분야에서도 활용이 확대되고 있습니다. 이러한 가치 제안은 비침습적 영상 진단, 신속한 영상 획득, 마이크론 단위의 해상도, 그리고 질환의 진행 상황 및 치료 반응에 대한 재현성 있는 모니터링에 기반을 두고 있습니다.
OCT의 동향은 장비 중심의 영상 진단에서 연계된 진단 생태계로 전환되고 있습니다. 하드웨어의 혁신으로 스캔 속도, 침투 깊이, 시야, 화질이 향상된 한편, 소프트웨어의 발전으로 자동 분할, 질환 분류, 경과 시간별 분석, 그리고 전자건강기록(EHR)과의 워크플로우 통합이 가능해졌습니다.
인공지능(AI)은 OCT를 단순한 영상 획득에서 임상 의사결정 지원으로 전환하는 움직임을 가속화하고 있습니다. 대규모 안과 영상 데이터셋을 활용해 학습된 AI 모델은 망막 층 분할, 체액 감지, 녹내장 위험도 평가, 당뇨성 망막병증의 중증도 분류, 그리고 트리아지 워크플로우를 지원할 수 있습니다. 이러한 누적적인 효과로, 영상 판독 부담의 경감, 일관성 향상, 그리고 전문의의 개입이 필요한 환자에 대한 우선순위 결정의 신속화가 꼽힙니다.
아시아태평양은 환자 수가 많고, 당뇨병 유병률이 상승하며, 안과 의료 인프라가 확충되고, 중국, 인도, 일본, 한국, 호주, 동남아시아에서 의료 기술에 대한 투자가 급속히 증가함에 따라 OCT 도입 측면에서 가장 활기찬 지역 중 하나가 되고 있습니다. 일본과 한국은 여전히 고도의 영상 진단 시장을 형성하고 있는 반면, 중국과 인도에서는 병원의 현대화, 국내 의료 기술 개발, 그리고 당뇨성 망막병증, 녹내장, 노화성 망막 질환을 대상으로 한 선별 검사 노력을 통해 큰 도입 잠재력을 지니고 있습니다.
아세안(ASEAN) 국가들에서는 의료 제도 내에서 전문적인 안과 의료, 의료 관광, 도시 지역의 진단 역량이 확대됨에 따라 광간섭 단층촬영(OCT) 시장의 중요성이 커지고 있습니다. 싱가포르, 태국, 말레이시아, 인도네시아, 베트남, 필리핀에서는 OCT 도입 현황에 차이가 있지만, 일반적으로 사립 병원, 3차 의료기관, 전문 안과 클리닉이 도입을 주도하고, 그 후 2차 의료기관 및 지역 선별 검사 프로그램으로 널리 보급되는 경향을 보이고 있습니다.
미국은 탄탄한 안과 진료 체계, 학술 연구, 망막 질환 및 녹내장 관리 분야의 높은 활용도, 그리고 전문의의 업무 흐름에 영상 진단을 광범위하게 통합함으로써 전 세계 OCT 도입을 주도하고 있습니다. 한편, 캐나다에서는 병원 및 전문 클리닉 네트워크를 통해 안정적인 수요가 유지되고 있습니다. 멕시코와 브라질에서는 민간 의료 분야에 대한 투자가 증가하고, 도시 지역 및 전문 의료 네트워크에서 당뇨병성 안과 질환의 선별 검사가 더욱 중요시됨에 따라 OCT 이용 기회가 확대되고 있습니다.
업계 리더는 고품질 이미지, AI 기반 분석, 클라우드 연결, 효율적인 워크플로우 설계를 결합한 통합형 OCT 플랫폼을 우선적으로 고려해야 합니다. 촬영 시간 단축, 소견 간소화, 그리고 질환의 경과 추적을 지원하는 업체는 환자 수가 증가하는 상황에 직면한 임상의들에게 더 유리한 입지를 확보하게 될 것입니다.
본 조사 방법은 널리 인정받는 업계 기준에 부합하는 체계적인 시장 조사 접근 방식을 바탕으로 수립되었습니다. 이 조사 방법론은 공중보건 기관, 규제 당국, 과학 문헌, 임상 지침, 제품 자료, 의료 인프라 지표 및 동료 심사를 거친 증거에 기반한 2차 조사와, 기술, 수요, 도입 동향에 관한 전문가들의 해석을 결합한 것입니다.
광간섭 단층촬영(OCT)은 특수한 영상 진단 도구에서 정밀 진단, 만성 질환 모니터링, 그리고 AI를 활용한 임상 의사결정 지원의 핵심 축으로 진화하고 있습니다. 시장의 장기적인 동향은 고령화, 당뇨병 유병률 증가, 안과 검진 수요의 확대, 그리고 OCT 하드웨어 및 소프트웨어의 지속적인 개선에 힘입어 유지되고 있습니다.
The Optical Coherence Tomography Market is projected to grow by USD 4.01 billion at a CAGR of 9.08% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 2.18 billion |
| Estimated Year [2026] | USD 2.36 billion |
| Forecast Year [2032] | USD 4.01 billion |
| CAGR (%) | 9.08% |
Optical coherence tomography (OCT) has become a core imaging modality for high-resolution, cross-sectional visualization of tissue microstructure, with the strongest clinical adoption in ophthalmology and growing use in cardiology, dermatology, oncology, and endoscopy. Its value proposition is anchored in noninvasive imaging, rapid acquisition, micron-scale resolution, and repeatable monitoring of disease progression and treatment response.
The optical coherence tomography market is being shaped by rising eye disease burden, expanding diabetic retinopathy screening, aging populations, and broader use of OCT angiography, spectral-domain OCT, and swept-source OCT. With the International Diabetes Federation reporting more than 500 million adults living with diabetes globally and the World Health Organization identifying vision impairment as a major public health challenge, demand for reliable retinal imaging and early diagnosis continues to strengthen across hospitals, ophthalmology clinics, ambulatory centers, and research settings.
The OCT landscape is shifting from device-centered imaging toward connected diagnostic ecosystems. Hardware innovation has improved scan speed, penetration depth, field of view, and image quality, while software advances are enabling automated segmentation, disease classification, longitudinal analytics, and workflow integration with electronic health records.
Clinical use is also expanding beyond traditional retinal imaging. Swept-source OCT supports deeper visualization of choroidal and anterior segment structures, OCT angiography enables dye-free vascular assessment, and catheter-based OCT supports intravascular imaging for coronary artery disease evaluation. These shifts are increasing the strategic importance of interoperability, cloud-enabled review, remote screening, and user-friendly systems designed for both specialist and distributed care environments.
Artificial intelligence is accelerating the transition of OCT from image acquisition to clinical decision support. AI models trained on large ophthalmic imaging datasets can support retinal layer segmentation, fluid detection, glaucoma risk assessment, diabetic retinopathy grading, and triage workflows. The cumulative impact is reduced reading burden, improved consistency, and faster prioritization of patients needing specialist intervention.
The strongest near-term opportunity is not replacing clinicians but augmenting them. AI-enabled OCT can help standardize interpretation across care sites, support population-scale screening, and improve monitoring for chronic retinal diseases such as age-related macular degeneration and diabetic macular edema. However, leaders must address model validation, data diversity, cybersecurity, regulatory compliance, explainability, and clinical governance to ensure safe deployment.
Asia-Pacific is one of the most dynamic regions for OCT adoption due to large patient populations, rising diabetes prevalence, expanding ophthalmology infrastructure, and rapid medical technology investment in China, India, Japan, South Korea, Australia, and Southeast Asia. Japan and South Korea remain advanced imaging markets, while China and India offer substantial adoption potential through hospital modernization, domestic medical technology development, and screening initiatives addressing diabetic retinopathy, glaucoma, and age-related retinal disease.
North America continues to demonstrate high OCT penetration due to established reimbursement pathways, strong specialist networks, clinical research activity, and early adoption of advanced ophthalmic diagnostics in the United States and Canada. Europe benefits from mature healthcare systems, strong regulatory oversight, aging populations, and broad adoption across Germany, France, Italy, Spain, and the United Kingdom, while Latin America is expanding access through private healthcare investment and public eye-health programs, especially in Brazil and Mexico.
The Middle East is investing in specialty hospitals, diabetes care, and premium diagnostic infrastructure across markets such as Saudi Arabia and the United Arab Emirates. Africa remains underpenetrated but strategically important because preventable vision loss, limited ophthalmologist density in many countries, and diabetic eye disease create a strong need for scalable, cost-effective OCT screening models supported by training, teleophthalmology, mobile eye-care services, and public-private partnerships.
ASEAN markets are gaining relevance as healthcare systems expand specialty eye care, medical tourism, and urban diagnostic capacity. Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines present varied OCT adoption profiles, with private hospitals, tertiary centers, and specialist ophthalmology clinics typically leading deployment before broader diffusion into secondary care and community screening programs.
The GCC is a high-opportunity group for premium OCT systems because of strong healthcare infrastructure spending, high diabetes burden, and national strategies focused on specialty care quality. The European Union benefits from harmonized medical device regulation under the Medical Device Regulation framework, large aging populations, and strong ophthalmology networks, although procurement cycles, clinical evidence requirements, and health technology assessment processes can lengthen commercialization timelines.
BRICS countries represent scale-driven demand, with China, India, and Brazil offering substantial patient volumes and Russia and South Africa showing selective adoption in urban and tertiary centers. G7 markets remain innovation leaders due to advanced research, reimbursement sophistication, established retinal and glaucoma care pathways, and high clinician awareness. NATO countries, while not a healthcare bloc, include many advanced medical systems where defense-adjacent innovation, cybersecurity expectations, data protection, and resilient supply chains influence digital health and imaging procurement decisions.
The United States leads global OCT adoption through strong ophthalmology practices, academic research, high utilization in retinal disease and glaucoma management, and broad integration of imaging into specialist workflows, while Canada maintains steady demand through hospital and specialty clinic networks. Mexico and Brazil are expanding OCT access as private healthcare investment grows and diabetic eye disease screening becomes more prominent across urban centers and specialty care networks.
In Europe, the United Kingdom, Germany, France, Italy, and Spain support mature OCT demand through aging demographics, public health systems, specialty care networks, and established clinical guidelines for retinal disease management. Germany stands out for engineering strength and advanced clinical adoption, while the United Kingdom emphasizes evidence-based care pathways and structured ophthalmology referral systems. France, Italy, and Spain continue to benefit from strong public ophthalmic care networks, and Russia maintains demand in major urban centers, though procurement and supply conditions can vary.
China is scaling OCT use through hospital expansion, ophthalmology department modernization, and domestic medical device capabilities, while India's growth is tied to diabetes burden, private ophthalmology chains, screening programs, and affordability-focused models. Japan remains a highly sophisticated imaging market with advanced clinical adoption and an aging population, Australia benefits from strong specialist access and diabetic eye-screening practices, and South Korea combines advanced healthcare infrastructure with rapid uptake of digital diagnostics and high acceptance of precision imaging technologies.
Industry leaders should prioritize integrated OCT platforms that combine high-quality imaging, AI-assisted analytics, cloud connectivity, and efficient workflow design. Vendors that reduce acquisition time, simplify interpretation, and support longitudinal disease monitoring will be better positioned with clinicians facing rising patient volumes.
Manufacturers should localize strategies by region, balancing premium swept-source OCT and OCT angiography systems in mature markets with durable, affordable, and easy-to-use systems in emerging markets. Partnerships with hospitals, academic centers, teleophthalmology providers, diabetes screening programs, and public eye-health initiatives can accelerate adoption while generating real-world evidence.
Leaders should also invest in regulatory readiness, cybersecurity, interoperability, and ethical AI governance. Transparent model performance, diverse training data, post-market monitoring, and clear clinical accountability will be essential for building trust in AI-enabled OCT solutions and securing adoption across regulated healthcare environments.
Research methodology is developed using a structured market intelligence approach aligned with recognized industry standards. The methodology combines secondary research from public health agencies, regulatory bodies, scientific literature, clinical guidelines, product documentation, healthcare infrastructure indicators, and peer-reviewed evidence with expert interpretation of technology, demand, and adoption trends.
Insights are triangulated across disease burden, demographic change, reimbursement dynamics, installed-base maturity, innovation pipelines, and regional healthcare investment patterns. The analysis emphasizes verified, data-backed signals such as diabetes prevalence, aging population trends, ophthalmic disease burden, medical device regulation, and documented adoption of OCT in ophthalmology, intravascular imaging, and adjacent clinical applications.
Optical coherence tomography is evolving from a specialized imaging tool into a central pillar of precision diagnostics, chronic disease monitoring, and AI-enabled clinical decision support. The market's long-term trajectory is supported by aging populations, rising diabetes prevalence, broader eye-screening needs, and continuous improvements in OCT hardware and software.
Organizations that align innovation with clinical workflow, affordability, regulatory quality, and regional access models will be best positioned to address demand. As OCT imaging becomes more connected, automated, and data-rich, its role in ophthalmology and adjacent specialties is expected to deepen across both developed and emerging healthcare systems.